<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435252</url>
  </required_header>
  <id_info>
    <org_study_id>Add-On cetuximab</org_study_id>
    <nct_id>NCT01435252</nct_id>
  </id_info>
  <brief_title>A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab</brief_title>
  <official_title>A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sixty patients with advanced squamous cell carcinomas of the head and neck will be enrolled&#xD;
      in this study. Patients are treated with standard chemoradiation in combination with&#xD;
      concurrent add-on cetuximab. Subsequently patients are randomized to cetuximab consolidation&#xD;
      therapy (three months, Arm A) versus no consolidation therapy (Arm B). The aim of this study&#xD;
      is to investigate if cetuximab consolidation therapy improves the 2-year locoregional control&#xD;
      rate.&#xD;
&#xD;
        -  Trial with medicinal product&#xD;
&#xD;
        -  Trial with radiotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study translates our preclinical findings that concurrent and consolidation&#xD;
      cetuximab improves efficacy of RT into the clinic. It is a phase II, randomized, open-label,&#xD;
      single center study in patients with locoregionally advanced stage III-IV and/or total gross&#xD;
      tumor volume (tGTV) &gt; 70cc head and neck cancer. This study population is at high risk for&#xD;
      locoregional recurrence after chemoradiation alone. Tumor stages to be included are T3-4 Nx,&#xD;
      Tx N2b-N3 (N2b only if ≥ 3 ipsilateral nodes involved) M0 and/or tGTV &gt;70 cc (any T, any N,&#xD;
      M0) squamous cell cancers of the head and neck (HNSCC). All patients will receive in, the so&#xD;
      called 'Induction Phase' standard chemoradiation (RT up to 70 Gy in combination with weekly&#xD;
      CDDP 40 mg/m2) and add-on concurrent cetuximab (loading Dose 400 mg/m2, concurrent dose 250&#xD;
      mg/m2 weekly). The patients are randomized to either add-on consolidation cetuximab (500&#xD;
      mg/m2 biweekly x 6 over 12 weeks) (Arm A) or no further treatment (Arm B). Randomization will&#xD;
      take place after Induction Phase. The total number of patients to be included into the study&#xD;
      is 60 (30 patients per arm). Up to 6 patients may be replaced in case of early drop out to&#xD;
      reach that aim.&#xD;
&#xD;
      The sample size of 60 patients is considered to be sufficient to collect first information on&#xD;
      clinical efficacy and the possible impact of various biomarkers on clinical endpoints. If the&#xD;
      results of this study will demonstrate that the novel treatment regimen is safe and&#xD;
      efficacious, a randomized multicenter phase III study will follow.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2011</start_date>
  <completion_date type="Actual">October 25, 2017</completion_date>
  <primary_completion_date type="Actual">October 25, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional tumor control</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis free survival (MFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological surrogate markers</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <condition>Hypopharyngeal Cancer</condition>
  <condition>Laryngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with chemoradiation in combination with concurrent cetuximab. Two weeks after end of chemoradiation the consolidation phase will start and patients will receive biweekly consolidation cetuximab, maximally 6 infusions over 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with chemoradiation in combination with concurrent cetuximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Erbitux®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  T3-4 Nx M0; Tx N2b-3 M0 (N2b only if ≥ 3 ipsilateral nodes involved) and/or total GTV&#xD;
             &gt; 70 cc (any T, any N, M0)&#xD;
&#xD;
          -  biopsy proven squamous cell cancer&#xD;
&#xD;
          -  primary tumor location in oral cavity, oropharynx, hypopharynx or larynx&#xD;
&#xD;
          -  Patients with CUP (cancer of unknown primary) syndrome in case they have advanced&#xD;
             lymph node metastases (Tx N2b-3 M0 (N2b only if ≥ 3 ipsilateral nodes involved).-&#xD;
             Indication for chemoradiation (RT + Cisplatin)&#xD;
&#xD;
          -  curative treatment intent&#xD;
&#xD;
          -  Start of chemoradiation within the recruitment time frame&#xD;
&#xD;
          -  Performance Status WHO/ECOG: 0-1&#xD;
&#xD;
          -  Age between 18 and 75 years&#xD;
&#xD;
          -  No previous chemotherapy or RT for cancer of the head and neck&#xD;
&#xD;
          -  Women of childbearing potential and male participants must agree to use a medically&#xD;
             effective means of birth control throughout their participation in the treatment phase&#xD;
             of the study (until at least 60 days following the last study treatment&#xD;
&#xD;
          -  Patient must sign informed consent prior to study entry.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Cancer of the nasopharynx&#xD;
&#xD;
          -  Any neoadjuvant chemotherapy prior to screening&#xD;
&#xD;
          -  Treatment with other investigational drugs within 4 weeks&#xD;
&#xD;
          -  History of malignancy other than basal cell skin cancer unless disease free for a&#xD;
             minimum of 3 years.&#xD;
&#xD;
          -  Uncontrolled claudication, bleeding, or thromboembolic disorders at screening&#xD;
&#xD;
          -  Patients receiving heparin, warfarin or phenprocoumon therapy are ineligible-&#xD;
             Uncontrolled and severe hypertension at screening according to the judgement of the&#xD;
             investigator.&#xD;
&#xD;
          -  Current uncontrolled cardiac disease: Unstable angina, New York Heart Association&#xD;
             (NYHA) Grade II or greater congestive heart failure, history of myocardial infarction&#xD;
             within 12 months, significant arrhythmias&#xD;
&#xD;
          -  Left ventricular function &lt; 45 % (determination of left ventricular function required&#xD;
             when history of cardiac disease)&#xD;
&#xD;
          -  History of stroke within 6 months&#xD;
&#xD;
          -  Major surgical procedure, or significant traumatic injury within 28 days prior to&#xD;
             screening; anticipation of need for major surgical procedure during the course of the&#xD;
             study.&#xD;
&#xD;
          -  Acute bacterial or fungal infection requiring intravenous antibiotics at screening&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness&#xD;
             requiring hospitalization or precluding study therapy at screening&#xD;
&#xD;
          -  Pregnant (positive pregnancy test) or lactating&#xD;
&#xD;
          -  Previous organ transplantation&#xD;
&#xD;
          -  Any immune suppressive therapy&#xD;
&#xD;
          -  Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition because&#xD;
             study treatment might be immuno-suppressive (Note: HIV testing only required if&#xD;
             clinically indicated)&#xD;
&#xD;
          -  Any uncontrolled condition, which in the opinion of the investigator, would interfere&#xD;
             with the safe and timely completion of study procedures.&#xD;
&#xD;
          -  Preexisting renal insufficiency with impaired creatinine clearance (&lt;60ml/min) and/or&#xD;
             increased plasma creatinine (&gt;106 µmol/l) at screening&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra- abdominal&#xD;
             abscess within 6 months prior to screening&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  AST, ALT, or bilirubin &gt; 1.5 x normal&#xD;
&#xD;
          -  Preexisting absolute neutrophil count (ANC) &lt; 1,800 cells/mm3&#xD;
&#xD;
          -  Platelets &lt; 100,000 103/µl at screening&#xD;
&#xD;
          -  PTT &gt; 1.5 x normal&#xD;
&#xD;
          -  WBC &lt; 4000 103/µl&#xD;
&#xD;
          -  Hb &lt; 11 g/dl at screening (Note: The use of transfusion or other intervention to&#xD;
             achieve Hb &gt; 11 g/dl is possible)&#xD;
&#xD;
          -  Contraindication to CDDP&#xD;
&#xD;
          -  Known allergy to cetuximab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Riesterer, Leitender Arzt</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2011</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Oliver Riesterer</investigator_full_name>
    <investigator_title>Leitender Arzt</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Hypopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

